JP2005515407A - アテローム硬化症の予後マーカーとしての可溶性ｃｄ４０ｌ（ｃｄ１５４） - Google Patents

アテローム硬化症の予後マーカーとしての可溶性ｃｄ４０ｌ（ｃｄ１５４） Download PDF

Info

Publication number
JP2005515407A
JP2005515407A JP2003542897A JP2003542897A JP2005515407A JP 2005515407 A JP2005515407 A JP 2005515407A JP 2003542897 A JP2003542897 A JP 2003542897A JP 2003542897 A JP2003542897 A JP 2003542897A JP 2005515407 A JP2005515407 A JP 2005515407A
Authority
JP
Japan
Prior art keywords
agent
subject
scd40l
risk
individual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003542897A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005515407A5 (https=
Inventor
シェーンベック，ウベ
リドカー，ポール，エム．
リビー，ピーター
Original Assignee
ザ ブライアム アンド ウィミンズ ホスピタル インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ブライアム アンド ウィミンズ ホスピタル インコーポレーテッド filed Critical ザ ブライアム アンド ウィミンズ ホスピタル インコーポレーテッド
Publication of JP2005515407A publication Critical patent/JP2005515407A/ja
Publication of JP2005515407A5 publication Critical patent/JP2005515407A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G01N33/567—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds utilising isolate of tissue or organ as binding agent
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2003542897A 2001-11-05 2002-11-05 アテローム硬化症の予後マーカーとしての可溶性ｃｄ４０ｌ（ｃｄ１５４） Pending JP2005515407A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33884101P 2001-11-05 2001-11-05
PCT/US2002/035505 WO2003040691A2 (en) 2001-11-05 2002-11-05 Soluble cd40l(cd154) as a prognostic marker of atherosclerotic diseases

Publications (2)

Publication Number Publication Date
JP2005515407A true JP2005515407A (ja) 2005-05-26
JP2005515407A5 JP2005515407A5 (https=) 2006-04-20

Family

ID=23326383

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003542897A Pending JP2005515407A (ja) 2001-11-05 2002-11-05 アテローム硬化症の予後マーカーとしての可溶性ｃｄ４０ｌ（ｃｄ１５４）

Country Status (7)

Country Link
US (2) US7189518B2 (https=)
EP (1) EP1451577A4 (https=)
JP (1) JP2005515407A (https=)
KR (1) KR20040068544A (https=)
CN (1) CN1613012A (https=)
CA (1) CA2464531A1 (https=)
WO (1) WO2003040691A2 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006508367A (ja) * 2002-11-16 2006-03-09 デイド・ベーリング・マルブルク・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング 心血管疾患における生化学的マーカーの組合せとしてのｓＣＤ４０Ｌ，ＰＡＰＰ−Ａおよび胎盤増殖因子（ＰｌＧＦ）
JP2018135330A (ja) * 2012-08-16 2018-08-30 クリティカル ケア ダイアグノスティクス インコーポレイテッド 高血圧症を発症するリスクを予測するための方法
JP7584125B2 (ja) 2020-11-02 2024-11-15 国立大学法人千葉大学 心血管イベントの発症リスクの検査方法

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6727102B1 (en) * 1997-06-20 2004-04-27 Leuven Research & Development Vzw Assays, antibodies, and standards for detection of oxidized and MDA-modified low density lipoproteins
US6309888B1 (en) * 1998-09-04 2001-10-30 Leuven Research & Development Vzw Detection and determination of the stages of coronary artery disease
WO2002012266A1 (en) 2000-08-05 2002-02-14 Glaxo Group Limited 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
WO2002018324A2 (en) 2000-08-29 2002-03-07 Nobex Corporation Immunoregulatory compounds, derivatives thereof and their use
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
PT1383786E (pt) 2001-04-30 2008-12-30 Glaxo Group Ltd Derivados anti-inflamatórios de éster 17.beta-carbotioato de androstano com um grupo éster ciclíco na posição 17.alfa
US7642286B2 (en) * 2001-06-21 2010-01-05 Andrx Pharmaceuticals, Inc. Stable pharmaceutical compositions containing pravastatin
US8048924B2 (en) * 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
JP2005515407A (ja) * 2001-11-05 2005-05-26 ザ ブライアム アンド ウィミンズ ホスピタル インコーポレーテッド アテローム硬化症の予後マーカーとしての可溶性ｃｄ４０ｌ（ｃｄ１５４）
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
EP1530047A1 (en) * 2003-11-07 2005-05-11 Roche Diagnostics GmbH Proximal markers of arterial thrombosis and inflammation for risk stratification of coronary heart disease
US20050181451A1 (en) * 2004-02-12 2005-08-18 Bates Harold M. Detection of asymptomatic coronary artery disease using atherogenic proteins and acute phase reactants
WO2005087266A1 (en) * 2004-03-05 2005-09-22 Vddi Pharmaceuticals Combination therapy for inhibition of platelet aggregation
WO2005110422A2 (en) * 2004-05-19 2005-11-24 Boehringer Ingelheim International Gmbh Treatment of diseases associated with altered level of amyloid beta peptides
DE102004028303A1 (de) 2004-06-11 2005-12-29 Roche Diagnostics Gmbh Verfahren und Vorrichtung zum Nachweis von Analyten
EP1615035B1 (en) * 2004-07-07 2007-06-06 F.Hoffmann-La Roche Ag Multimarker panel for diabetes type 1 and 2
DK1773767T3 (en) 2004-07-07 2016-03-21 Biocon Ltd Synthesis of azo bound in immune regulatory relations
US7560227B2 (en) * 2005-02-28 2009-07-14 University Of Massachusetts Biomarkers of vulnerable atherosclerotic plaques and methods of use
WO2007042778A2 (en) * 2005-10-11 2007-04-19 St George's Enterprises Limited Monitoring cardiovascular disease by determining the expression of kir2ds2 and/or dap12
EP2431746A1 (en) 2005-11-17 2012-03-21 Biogen Idec MA Inc. Platelet aggregation assays
EP2302395B1 (en) 2006-06-07 2015-04-15 Health Diagnostic Laboratory, Inc. Markers associated with arteriovascular events and methods of use thereof
US20120034629A1 (en) * 2007-08-17 2012-02-09 Siemens Healthcare Diagnostics Inc. Prediction of non-fatal and fatal atherothrombotic events
US9359633B2 (en) * 2007-11-05 2016-06-07 Nordic Bioscience A/S Biochemical markers for CVD risk assessment
AU2010324544A1 (en) 2009-11-27 2012-06-21 Baker Idi Heart And Diabetes Institute Holdings Limited Lipid biomarkers for stable and unstable heart disease
US20190263888A1 (en) 2010-10-19 2019-08-29 Op-T Llc Therapeutic peptides and methods for treating autoimmune related disease
JP5857312B2 (ja) * 2011-08-11 2016-02-10 積水メディカル株式会社 心疾患診断マーカー
CN103163295B (zh) * 2011-12-08 2015-11-18 吴宗贵 一种用于急性冠脉综合征的液相芯片试剂盒以其制备方法
EP2968292A4 (en) * 2013-03-15 2016-11-23 Intermune Inc METHOD FOR IMPROVING MICROVASCULAR INTEGRITY
ES3031007T3 (en) * 2017-11-10 2025-07-03 Op T Llc Peptide for preventing, modulating and/or reducing cardiovascular disease
US11793854B2 (en) 2019-03-21 2023-10-24 Op-T Llc Methods for reducing symptoms of multiple sclerosis using a six-amino acid long peptide that inhibits CD40-CD150 interaction
US12048734B2 (en) 2020-04-17 2024-07-30 Op-T Llc Bioactive peptides and methods of use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5358844A (en) * 1993-02-18 1994-10-25 Brigham And Women's Hospital, Inc. Preservation of blood platelets
US5622867A (en) * 1994-10-19 1997-04-22 Lifecell Corporation Prolonged preservation of blood platelets
US5919614A (en) * 1994-10-19 1999-07-06 Lifecell Corporation Composition comprising three platelet lesion inhibitors for platelet storage
WO1998020155A1 (en) * 1996-11-08 1998-05-14 New York Society For The Relief Of The Ruptured And Crippled Maintaining The Hospital For Special Surgery Diagnostic methods using cd40 ligand assay
ATE530180T1 (de) 1997-04-02 2011-11-15 Brigham & Womens Hospital Verfahren zur ermittlung der individualen risikoprofile atherosklerotischen erkrankungen
US6117911A (en) * 1997-04-11 2000-09-12 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
AU782386C (en) 1999-08-31 2006-08-10 Brigham And Women's Hospital Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases
JP2001322933A (ja) 2000-05-15 2001-11-20 Ucb Sa Ｃｄ４０シグナル遮断剤
JP2005515407A (ja) * 2001-11-05 2005-05-26 ザ ブライアム アンド ウィミンズ ホスピタル インコーポレーテッド アテローム硬化症の予後マーカーとしての可溶性ｃｄ４０ｌ（ｃｄ１５４）

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006508367A (ja) * 2002-11-16 2006-03-09 デイド・ベーリング・マルブルク・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング 心血管疾患における生化学的マーカーの組合せとしてのｓＣＤ４０Ｌ，ＰＡＰＰ−Ａおよび胎盤増殖因子（ＰｌＧＦ）
JP2018135330A (ja) * 2012-08-16 2018-08-30 クリティカル ケア ダイアグノスティクス インコーポレイテッド 高血圧症を発症するリスクを予測するための方法
JP7584125B2 (ja) 2020-11-02 2024-11-15 国立大学法人千葉大学 心血管イベントの発症リスクの検査方法

Also Published As

Publication number Publication date
US7189518B2 (en) 2007-03-13
WO2003040691A3 (en) 2003-11-13
EP1451577A4 (en) 2006-03-15
US20080058360A1 (en) 2008-03-06
US20030152566A1 (en) 2003-08-14
KR20040068544A (ko) 2004-07-31
WO2003040691A2 (en) 2003-05-15
CN1613012A (zh) 2005-05-04
CA2464531A1 (en) 2003-05-15
EP1451577A2 (en) 2004-09-01

Similar Documents

Publication Publication Date Title
US7189518B2 (en) Soluble CD40L(CD154) as a prognostic marker of atherosclerotic diseases
AU782386C (en) Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases
US8147817B2 (en) IL-33 in the treatment and diagnosis of diseases and disorders
US9551708B2 (en) Methods of treating a subject having heart failure
US8846321B2 (en) Association of levels of HDL-cholesterol apolipoprotein CIII with the risk of coronary heart disease and cardiovascular events
US11435363B2 (en) Relevance of achieved levels of markers of systemic inflammation following treatment
US7964614B2 (en) Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease
WO2003088811A2 (en) Gelsolin as a prognostic marker of artherosclerotic diseases
AU2002343620A1 (en) Soluble CD40L(CD154) as a prognostic marker of atherosclerotic diseases
EP1520590A1 (en) Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases
EP1767223A1 (en) Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases
AU2005225101A1 (en) Systemic inflammatory markers as diagnostic tools in the prevention of atherosclered diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051104

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060221

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20081001

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081028

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090331